Program
eloralintide
Also written as “Eloralintide”, “LY3841136” and “eloralintide and tirzepatide”.
In Eli Lilly’s own words, LY3841136 (eloralintide) is a biologic entity that acts as a selective amylin receptor agonist.
. Its studies are mostly in Obesity · Kidney Failure, Chronic · Osteoarthritis · Sleep Apnea, Obstructive · Hepatic Insufficiency, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 2617 open or running | phase 3since Dec 5, 2025 | Mar 24, 2022 | Dec 2026phase 1 · NCT07738614 |
- Named in Eli Lilly’s own pipeline as
Eloralintide
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Mar 24, 2022.
- Mar 1, 20242 phase 1 studies in ObesityNCT06297616, NCT06345066
- Aug 11, 2024Named eloralintideINNProposed as its International Nonproprietary Name in WHO's List 131 · before, LY3841136
- Sep 17, 2024Phase 2 study in ObesityNCT06603571 · 367 enrolled · United States, Argentina
- Apr 1, 20252 phase 1 studiesNCT06916091, NCT06916065
- Oct 9, 2025Phase 2 study in ObesityNCT07215559 · 200 enrolled · United States, Argentina, Australia and more
- Dec 5, 2025Phase 3 study in OverweightPhase 3 reachedNCT07282600 · 1,035 planned · United States, China, Czechia and more
- Jan 5, 20264 phase 3 studiesNCT07321886, NCT07353931, NCT07369011 and 1 more
- Feb 4, 20262 phase 1 studiesNCT07401862, NCT07426380
- May 11, 2026Phase 2 study in OverweightNCT07589608 · 400 planned · United States
- Jun 19, 2026Phase 1 study in OverweightNCT07665879 · 115 planned · Germany, Sweden
- Jul 9, 20262 phase 1 studiesNCT07701083, NCT07738614
- Aug 11, 2026Phase 1 study in ObesityNCT07765511 · 60 planned · Japan
- Sep 3, 2026Phase 1 study in ObesityNCT07808060 · 34 planned · United States
- Oct 12, 20263 phase 3 studies in ObesityNCT07881458, NCT07881432, NCT07900633
- Nov 9, 2026Phase 1 study in HealthyNCT07935304 · 90 planned · United States, Singapore
Ahead
- Dec 2026Primary completion: phase 1 study in ObesityNCT07738614
- Mar 2027Primary completion: phase 1 study in Hepatic InsufficiencyNCT07401862
- Mar 2027Primary completion: phase 2 study in ObesityNCT07215559
- Apr 2027Primary completion: phase 1 study in HealthyNCT07935304
TargetBeta
“LY3841136 (eloralintide) is a biologic entity that acts as a selective amylin receptor agonist.”company, read by Claude · source
Other programs on CALCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cagrilintide | Novo Nordisk | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| petrelintiderule | Zealand Pharma | phase 3 | 11 |
| ABBV-295 | AbbVie | phase 2 | 5 |
| PF-08653945 | Pfizer | phase 2 | 2 |
| GUB014295 | AbbVie | phase 1 | 1 |
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07935304Healthy · United States, Singapore | 1 | Not yet recruiting | Apr 2027 | 90 |
| NCT07900633Obesity · United States, Argentina, Australia and more | 3 | Not yet recruiting | Nov 2029 | 3,000 |
| NCT07881458Obesity · United States, Argentina, Brazil and more | 3 | Recruiting | Oct 2029 | 1,000 |
| NCT07881432Obesity · United States, Argentina, China and more | 3 | Not yet recruiting | Oct 2029 | 2,115 |
| NCT07808060Obesity · United States | 1 | Recruiting | Jun 2027 | 34 |
| NCT07765511Obesity · Japan | 1 | Not yet recruiting | Jun 2027 | 60 |
| NCT07738614Obesity · United States, Singapore | 1 | Active, not recruiting | Dec 2026 | 56 |
| NCT07701083Healthy Volunteers · United States | 1 | Completed | Oct 29, 2026 | 58 |
| NCT07665879Overweight · Germany, Sweden | 1 | Recruiting | Aug 2027 | 115 |
| NCT07589608Overweight · United States | 2 | Recruiting | Sep 2027 | 400 |
| NCT07426380Kidney Diseases · United States | 1 | Completed | Oct 6, 2026 | 28 |
| NCT07401862Hepatic Insufficiency · United States, Hungary | 1 | Recruiting | Mar 2027 | 36 |
| NCT07392190Overweight · United States, Australia, Belgium and more | 3 | Recruiting | Jun 2028 | 900 |
| NCT07369011Sleep Apnea, Obstructive · United States, Australia, Brazil and more | 3 | Recruiting | Mar 2028 | 800 |
| NCT07353931Osteoarthritis · United States, Argentina, Belgium and more | 3 | Recruiting | Mar 2028 | 900 |
| NCT07321886Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Mar 2028 | 1,980 |
| NCT07282600Overweight · United States, China, Czechia and more | 3 | Recruiting | Jan 2028 | 1,035 |
| NCT07215559Obesity · United States, Argentina, Australia and more | 2 | Active, not recruiting | Mar 2027 | 200 |
| NCT06916091Obesity · Singapore | 1 | Completed | Sep 9, 2025 | 30 |
| NCT06916065Overweight · United States | 1 | Completed | Jan 19, 2026 | 188 |
| NCT06603571Obesity · United States, Argentina | 2 | Completed | Jul 1, 2026 | 367 |
| NCT06345066Obesity · United States | 1 | Completed | Sep 29, 2025 | 96 |
| NCT06297616Obesity · Japan | 1 | Completed | Nov 21, 2025 | 128 |
| NCT06230523Obesity · United States | 2 | Completed | May 30, 2025 | 263 |
| NCT06143956Obesity · United States, Argentina | 2 | Recruiting | Sep 2027 | 1,481 |
| NCT05295940Obesity · United States | 1 | Completed | Jan 25, 2024 | 148 |
How it is read
Names in the registry
- “Eloralintide”, 19 entries
- “LY3841136”, 7 entries
- “eloralintide and tirzepatide”, 2 entries
- “Eloralintide and Tirzepatide”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 20 studies
- Kidney Failure, Chronic, 1 study
- Osteoarthritis, 1 study
- Sleep Apnea, Obstructive, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.